Searchlight Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Searchlight Pharma's estimated annual revenue is currently $15.9M per year.
- Searchlight Pharma's estimated revenue per employee is $201,000
Employee Data
- Searchlight Pharma has 79 Employees.
- Searchlight Pharma grew their employee count by 23% last year.
Searchlight Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Sales Marketing | Reveal Email/Phone |
2 | Chief Innovation Officer | Reveal Email/Phone |
3 | Chief Financial & Operations Officer | Reveal Email/Phone |
Searchlight Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.2M | 16 | 7% | N/A | N/A |
#2 | $30.2M | 150 | 1% | N/A | N/A |
#3 | $10.7M | 100 | 5% | $39.7M | N/A |
#4 | $104.3M | 519 | 22% | N/A | N/A |
#5 | $47.8M | 238 | N/A | N/A | N/A |
#6 | $15.5M | 77 | 5% | N/A | N/A |
#7 | $395.8M | 1969 | 7% | N/A | N/A |
#8 | $187.3M | 932 | 6% | N/A | N/A |
#9 | $361.6M | 1799 | 6% | N/A | N/A |
#10 | $27.5M | 137 | 0% | N/A | N/A |
What Is Searchlight Pharma?
Searchlight Pharma aspires to become a leading Canadian-based specialty healthcare company through best-in-class execution of the acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness.
keywords:N/AN/A
Total Funding
79
Number of Employees
$15.9M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Searchlight Pharma News
2022-04-17 - Global Olsalazine Sodium Market Key Player Analysis and ...
Pfizer; Tianjin Lisheng Pharma; CR Sanjiu; Nirvana; Searchlight Pharma; Pharmanovia. ACCESS FULL REPORT: https://www.marketsandresearch.biz/...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $16.6M | 79 | 65% | N/A |
#2 | $19.4M | 79 | N/A | N/A |
#3 | $25.5M | 79 | 1% | N/A |
#4 | $12.2M | 79 | N/A | N/A |
#5 | $11.5M | 79 | -18% | N/A |